Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by GAURI R VARADHACHARY and MICHAEL JAMES OVERMAN.
GAURI R VARADHACHARY
Connection Strength
3.955
MICHAEL JAMES OVERMAN
  1. Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma. BMC Cancer. 2016 08 22; 16:668.
    View in: PubMed
    Score: 0.561
  2. Adjuvant chemotherapy for resected periampullary adenocarcinoma. JAMA. 2012 Nov 14; 308(18):1855; author reply 1855-6.
    View in: PubMed
    Score: 0.432
  3. Clinical Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Malignant Peritoneal Mesothelioma. JAMA Netw Open. 2021 08 02; 4(8):e2119934.
    View in: PubMed
    Score: 0.198
  4. Defining a Distinct Immunotherapy Eligible Subset of Patients with Cancer of Unknown Primary Using Gene Expression Profiling with the 92-Gene Assay. Oncologist. 2020 11; 25(11):e1807-e1811.
    View in: PubMed
    Score: 0.186
  5. Retrospective Analysis of Taxane-Based Therapy in Small Bowel Adenocarcinoma. Oncologist. 2019 06; 24(6):e384-e386.
    View in: PubMed
    Score: 0.165
  6. Phase II Study of Panitumumab in RAS Wild-Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater. Oncologist. 2018 03; 23(3):277-e26.
    View in: PubMed
    Score: 0.154
  7. Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study. Cancer. 2017 May 15; 123(6):1011-1017.
    View in: PubMed
    Score: 0.143
  8. Cancer of Unknown Primary in Adolescents and Young Adults: Clinicopathological Features, Prognostic Factors and Survival Outcomes. PLoS One. 2016; 11(5):e0154985.
    View in: PubMed
    Score: 0.138
  9. Validation of histomolecular classification utilizing histological subtype, MUC1, and CDX2 for prognostication of resected ampullary adenocarcinoma. Br J Cancer. 2015 Jun 30; 113(1):64-8.
    View in: PubMed
    Score: 0.128
  10. Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome. PLoS One. 2013; 8(6):e65144.
    View in: PubMed
    Score: 0.112
  11. A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy. Ann Oncol. 2013 Sep; 24(9):2349-53.
    View in: PubMed
    Score: 0.112
  12. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol. 2009 Jun 01; 27(16):2598-603.
    View in: PubMed
    Score: 0.083
  13. Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest. 2008 Oct; 26(8):794-9.
    View in: PubMed
    Score: 0.081
  14. Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Invest New Drugs. 2008 Oct; 26(5):445-54.
    View in: PubMed
    Score: 0.079
  15. Feasibility and value of genomic profiling in cancer of unknown primary: real-world evidence from prospective profiling study. J Natl Cancer Inst. 2023 08 08; 115(8):994-997.
    View in: PubMed
    Score: 0.057
  16. Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation. Int J Radiat Oncol Biol Phys. 2022 11 01; 114(3):444-453.
    View in: PubMed
    Score: 0.053
  17. Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial. J Immunother Cancer. 2022 05; 10(5).
    View in: PubMed
    Score: 0.052
  18. Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. J Gastrointest Oncol. 2021 Oct; 12(5):2268-2274.
    View in: PubMed
    Score: 0.050
  19. Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov. 2021 11; 11(11):2738-2747.
    View in: PubMed
    Score: 0.049
  20. Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. Cancer Med. 2021 08; 10(15):5041-5050.
    View in: PubMed
    Score: 0.049
  21. Development and Validation of a Novel Nomogram for Individualized Prediction of Survival in Cancer of Unknown Primary. Clin Cancer Res. 2021 06 15; 27(12):3414-3421.
    View in: PubMed
    Score: 0.048
  22. Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. Ann Surg. 2021 04 01; 273(4):806-813.
    View in: PubMed
    Score: 0.048
  23. Cancer of Unknown Primary Presenting as Bone-Predominant or Lymph Node-Only Disease: A Clinicopathologic Portrait. Oncologist. 2021 04; 26(4):e650-e657.
    View in: PubMed
    Score: 0.048
  24. Sex Representation in Clinical Trials Associated with FDA Cancer Drug Approvals Differs Between Solid and Hematologic Malignancies. Oncologist. 2021 02; 26(2):107-114.
    View in: PubMed
    Score: 0.047
  25. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2020 09 01; 155(9):832-839.
    View in: PubMed
    Score: 0.046
  26. Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. Cancer Med. 2020 08; 9(15):5406-5415.
    View in: PubMed
    Score: 0.046
  27. Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. Ann Surg. 2020 06; 271(6):996-1002.
    View in: PubMed
    Score: 0.046
  28. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. Pancreatology. 2020 Apr; 20(3):501-504.
    View in: PubMed
    Score: 0.044
  29. Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer. Clin Cancer Res. 2020 03 15; 26(6):1385-1394.
    View in: PubMed
    Score: 0.044
  30. Sarcomatoid carcinoma presenting as cancers of unknown primary: a clinicopathological portrait. BMC Cancer. 2019 Oct 17; 19(1):965.
    View in: PubMed
    Score: 0.044
  31. Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018. JAMA Oncol. 2019 Oct 01; 5(10):e191870.
    View in: PubMed
    Score: 0.043
  32. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci U S A. 2019 01 29; 116(5):1692-1697.
    View in: PubMed
    Score: 0.041
  33. Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. J Immunother. 2018 Jul/Aug; 41(6):284-291.
    View in: PubMed
    Score: 0.040
  34. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma. J Hematol Oncol. 2018 05 30; 11(1):71.
    View in: PubMed
    Score: 0.040
  35. Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy. Cancer. 2018 04 15; 124(8):1701-1709.
    View in: PubMed
    Score: 0.039
  36. Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2017 Nov 01; 152(11):1048-1056.
    View in: PubMed
    Score: 0.038
  37. 4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. Clin Cancer Res. 2017 Dec 01; 23(23):7263-7275.
    View in: PubMed
    Score: 0.038
  38. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients. Ann Oncol. 2017 04 01; 28(4):741-747.
    View in: PubMed
    Score: 0.037
  39. Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater. Ann Surg Oncol. 2017 Jul; 24(7):2031-2039.
    View in: PubMed
    Score: 0.036
  40. A predictive model of inflammatory markers and patient-reported symptoms for cachexia in newly diagnosed pancreatic cancer patients. Support Care Cancer. 2017 06; 25(6):1809-1817.
    View in: PubMed
    Score: 0.036
  41. Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. J Gastrointest Surg. 2017 01; 21(1):164-174.
    View in: PubMed
    Score: 0.035
  42. Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. J Gastrointest Surg. 2016 12; 20(12):1975-1985.
    View in: PubMed
    Score: 0.035
  43. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Cancer. 2016 09 01; 122(17):2671-9.
    View in: PubMed
    Score: 0.035
  44. Expression and clinical significance of epidermal growth factor receptor and insulin-like growth factor receptor 1 in patients with ampullary adenocarcinoma. Hum Pathol. 2015 Sep; 46(9):1315-22.
    View in: PubMed
    Score: 0.032
  45. Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer? J Cachexia Sarcopenia Muscle. 2014 Dec; 5(4):307-13.
    View in: PubMed
    Score: 0.030
  46. Aberrant expression of p53, p21, cyclin D1, and Bcl2 and their clinicopathological correlation in ampullary adenocarcinoma. Hum Pathol. 2014 May; 45(5):1015-23.
    View in: PubMed
    Score: 0.029
  47. The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. Invest New Drugs. 2013 Oct; 31(5):1375-83.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.